GenMark Diagnostics' Q1 Revenues Rise 9 Percent | GenomeWeb

NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its first quarter revenues rose 9 percent thanks to strong sales of its XT-8 molecular diagnostics system.

For the three months ended March 31, the molecular diagnostics firm reported revenues of $11.1 million, up from $10.1 million a year ago, and beating the consensus Wall Street estimate of $10.7 million.

Revenues from product sales were $11.0 million, with licensing and other revenues rounding out the total.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.